We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Mint Tea for the Treatment of Nasal Polyps

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00465543
Recruitment Status : Completed
First Posted : April 25, 2007
Last Update Posted : December 9, 2011
Information provided by (Responsible Party):
Paul Keith, McMaster University

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of a new treatment for nasal polyps as compared to placebo (an inactive substance). The treatment involved is mint tea high in rosmarinic acid. Rosmarinic acid is a polyphenol, or a chemical substance found in certain plants such as oregano, rosemary, and the mints. It is the active ingredient in spearmint. The placebo used in this study will be mint tea low in rosmarininc acid. In this trial the amount of rosmarinic acid in the high rosmarinic acid tea, or study tea, will be 150mg. The placebo, or low rosmarinic acid tea, will contain 10mg of rosmarinic acid.

Condition or disease Intervention/treatment Phase
Nasal Polyps Other: Mint tea high in rosmarinic acid Other: Mint tea low in rosmarinic acid Phase 2

Detailed Description:

Nasal polyps are clear, glistening, grape-like structures that occur in two percent of adults and contain a large number of activated eosinophils - about 20% of the constituents of nasal polyp tissue.

The standard treatment for nasal polyp patients is intranasal steroids which, in troublesome cases, may follow a short course of oral steroids. Surgery is reserved for extremely large polyps and those who fail medical treatment. However, many patients tire of using nasal sprays or are troubled by side effects such as nasal irritation or bleeding. So, while all treatments offer some benefit, there is no gold standard.

Rosmarinic acid is categorized as a polyphenolia phytochemical, or a 'plant phenol' and is found in a variety of plants including the herbs oregano and rosemary, as well as the mints. Peppermint is one of the most widely used single ingredient in herbal teas. It has been found in vitro to have significant antimicrobial and antiviral properties, strong antioxidant and antitumor actions, and some antiallergenic ability. Human based research is limited.

A mint tea high in rosmarinic acid has recently been produced. Anecdotal evidence suggests that it may be beneficial for allergic rhinitis if taken prior to allergen exposure (personal communication). Other anecdotal evidence found a blunting of the sputum eosinophils following allergen challenge in allergic asthmatics (personal communication). This trial aims to study the effects of this mint tea high in rosmarinic acid in adults with bilateral nasal polyps, a condition characterized by chronic eosinophilic inflammation. The control treatment will be a mint tea low in rosmarinic acid.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind,Placebo-controlled, Randomized, Crossover Trial of Mint Tea High in Rosmarinic Acid in Adults With Nasal Polyposis
Study Start Date : May 2007
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: II
Arm 2 receives 4 weeks of placebo mint tea (consumed twice a day) followed by 4 weeks of washout and then a further 4 weeks of treatment with study mint tea (consumed twice a day).
Other: Mint tea low in rosmarinic acid
Mint tea low in rosmarininc acid contains 10mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.

Placebo Comparator: I
Arm 1 receives 4 weeks of treatment with mint tea high in rosmarinic acid, consumed twice a day. Treatment is followed by a 4 week wash-out phase. Subjects then enter a 4 week phase of placebo mint tea (low in rosmarinic acid), to be consumed twice a day.
Other: Mint tea high in rosmarinic acid
Mint tea high in rosmarininc acid contains 150mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.

Primary Outcome Measures :
  1. Nasal polyposis quality of life questionnaire [ Time Frame: Visits 2, 3,4,5 ]
  2. Nasal patency as assessed by use of the Clement-Clarke peak nasal inspiratory flow meter (PNIF) [ Time Frame: Daily ]

Secondary Outcome Measures :
  1. Nasal lavage eosinophils. [ Time Frame: Visits 1,2,3,4,5 ]
  2. Peripheral blood eosinophils [ Time Frame: Visits 2,3,4,5 ]
  3. Diary symptom scores. [ Time Frame: Daily ]
  4. Nasal polyp size on visual inspection. [ Time Frame: Visits 1,2,3,4,5 ]
  5. Subjects Global Assessment of symptoms [ Time Frame: Visits 3 and 5 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Subjects who are male or female aged 18 years or older.
  2. Subjects who have signed an informed consent agreement.
  3. Subjects with a history of nasal polyp symptoms during the previous 12 months.

Exclusion Criteria:

  1. Subjects with severe nasal polyps requiring immediate surgery.
  2. Subjects presenting with unilateral polyps.
  3. Subjects who have undergone surgery to treat their nasal polyps (nasal polypectomy) within one year prior to visit one.
  4. Subjects who have a known fungal infection of the nose and/or paranasal sinuses, nasal candidiasis, acute or chronic infectious sinusitis of viral or bacterial nature.
  5. Subjects who have had an upper respiratory tract infection within two weeks prior to Visit one or any time between Visit 1 and Visit 2.
  6. Subjects having cystic fibrosis, Young's syndrome, primary ciliary dyskinesia, known HIV infection or alcohol abuse.
  7. Subjects with clinically significant, uncontrolled evidence of cardiovascular, neurological, hepatic, renal, respiratory, or any other medical condition that may interfere with the study.
  8. Subjects with a recent history (within six months) of a clinically significant psychiatric disorder other than mild depression.
  9. Subjects who have any clinically relevant deviation from normal in the general physical examination.
  10. Subjects who have received any depot, systemic or oral corticosteroid in the previous three months prior to the start of the study.
  11. Subjects who are unable to cease treatment with intranasal steroids four weeks prior to Visit one.
  12. Subjects with a known hypersensitivity to mint.
  13. Females who are pregnant or lactating or are likely to become pregnant during the study or are less than 8 weeks postpartum. Women of childbearing age may be included if in the opinion of the investigator, they are taking adequate contraceptive measures.
  14. Subjects who are unable to follow the instructions within this protocol or known inability to attend all clinic visits within the intervals stated.
  15. Subjects who have participated in a clinical trial involving an investigational or marketed drug within four weeks of visit one.
  16. Subjects who are allergy skin test positive to a seasonal allergen which will be present when performing the trial, that has caused, within the past 2 years, a clinically significant deterioration in nasal symptoms.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00465543

Sponsors and Collaborators
Hamilton Health Sciences Corporation
Layout table for investigator information
Principal Investigator: Paul K. Keith Hamilton Health Sciences Corporation, McMaster Site
Keith PK, Conway M, Dolovich J. Development and validation of a nasal polyposis quality of life questionnaire. J Allergy Clin Immunol 1996;97:192(Abstract)
Keith PK, Ferrie P, Conway M, Waserman S, Schmuck ML, Denburg JA. A double-blind, placebo-controlled, randomized, crossover trial of montelukast in adults with nasal polyposis. Allergy Clin Immunol Int: J World Allergy Org, 2003; Supp 1:185.(Abstract)

Layout table for additonal information
Responsible Party: Paul Keith, Associate Professor, McMaster University
ClinicalTrials.gov Identifier: NCT00465543    
Other Study ID Numbers: 07-010
First Posted: April 25, 2007    Key Record Dates
Last Update Posted: December 9, 2011
Last Verified: December 2011
Keywords provided by Paul Keith, McMaster University:
Nasal polyposis
Mint tea
Additional relevant MeSH terms:
Layout table for MeSH terms
Nasal Polyps
Pathological Conditions, Anatomical
Nose Diseases
Respiratory Tract Diseases
Otorhinolaryngologic Diseases
Rosmarinic acid
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Platelet Aggregation Inhibitors
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors